125 related articles for article (PubMed ID: 25571293)
1. Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans.
Methaneethorn J; Kunyamee P; Jindasri W; Wattanasaovaluk W; Kraiboot A; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5715-8. PubMed ID: 25571293
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Methaneethorn J; Chamnansua M; Kaewdang N; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5711-4. PubMed ID: 25571292
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans.
Methaneethorn J; Chaiwong K; Pongpanich K; Sonsingh P; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5703-6. PubMed ID: 25571290
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole.
Lohitnavy M; Methaneethorn J; Chiang-Ngernthanyakool R; Tongpeng W; Chan-Im D; Phaohorm S
Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():3246-9. PubMed ID: 26736984
[TBL] [Abstract][Full Text] [Related]
6. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
Page SR; Yee KC
Intern Med J; 2014 Jul; 44(7):690-3. PubMed ID: 25041770
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
Rowan C; Brinker AD; Nourjah P; Chang J; Mosholder A; Barrett JS; Avigan M
Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):301-9. PubMed ID: 19206087
[TBL] [Abstract][Full Text] [Related]
8. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
[TBL] [Abstract][Full Text] [Related]
9. [Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].
Bastida C; Also MA; Pericas JM; Letang E; Tuset M; Miró JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):579-82. PubMed ID: 24913991
[TBL] [Abstract][Full Text] [Related]
10. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
[TBL] [Abstract][Full Text] [Related]
11. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers.
Offman E; Davidson M; Nilsson C
J Clin Lipidol; 2017; 11(3):739-748. PubMed ID: 28506390
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
[TBL] [Abstract][Full Text] [Related]
15. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
16. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
17. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Dingemanse J; Nicolas LB; van Bortel L
Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
[TBL] [Abstract][Full Text] [Related]
18. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Kanathur N; Mathai MG; Byrd RP; Fields CL; Roy TM
Tenn Med; 2001 Sep; 94(9):339-41. PubMed ID: 11550401
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
